| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we studied whether C-type natriuretic peptide (CNP) administration would exert an antiarrhythmic effect in rats after acute myocardial ischemia/reperfusion (I/R) and increase left ventricular diastolic distensibility in rats with HFpEF.
Study 1;Ventricular tachyarrhythmias were less frequent in rats after myocardial I/R who received CNP in comparison to rats. Importantly, CNP administration improved the mortality rate associated with myocardial I/R injury-induced arrhythmias. CNP administration also accelerated Akt and NO phosphorylation in cardiac tissues.
Study 2;The diastolic LV dysfunction in HFpEF model was improved by CNP, although arterial pressure was not affected. Furthermore, CNP attenuated an increase collagen volume fraction in LV. In conclusion, short-term infusion of CNP attenuated ventricular arrhythmia and long-term CNP administration improved diastolic function. These data suggest the potential usefulness of CNP for myocardial I/R injury and HFpEF.
|
